我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
143
10 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1983
进行中（未招募）
3
2.1%
已完成
73
51.0%
Enrolling By Invitation
1
0.7%
尚未招募
6
4.2%
招募中
32
22.4%
Unknown
24
16.8%
撤回
4
2.8%
暂无批准数据
• Exploratory analysis of the HERA trial reveals that ovarian function suppression (OFS) combined with endocrine therapy significantly improves long-term survival in premenopausal women with HER2-positive, hormone receptor-positive breast cancer. • The 10-year disease-free survival rate increased from 59.6% with tamoxifen alone to 70.9% with the addition of OFS, demonstrating a substantial benefit in disease control. • Overall survival rates at 10 years also saw a marked improvement, rising from 74.0% to 84.7% with the inclusion of OFS in the treatment regimen. • While OFS can be challenging due to toxicity, its use should be considered in selected high-risk patients to improve survival outcomes.
